Hologic, Inc. (NASDAQ:HOLX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $87.50.

HOLX has been the topic of several research analyst reports. Needham & Company LLC restated a "buy" rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an "overweight" rating in a report on Tuesday, July 30th. StockNews.com lowered shares of Hologic from a "strong-buy" rating to a "buy" rating in a report on Friday, September 27th. Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, Stephens restated an "overweight" rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th.

Hologic Trading Up 1.8 %

Shares of HOLX stock traded up $1.46 on Friday, hitting $82.33. 1,955,998 shares of the stock traded hands, compared to its average volume of 1,574,248. The stock has a market capitalization of $19.12 billion, a PE ratio of 28.00, a PEG ratio of 2.94 and a beta of 0.98. Hologic has a twelve month low of $66.53 and a twelve month high of $84.67. The firm's 50-day moving average price is $80.99 and its two-hundred day moving average price is $77.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Insider Buying and Selling

In related news, insider Brandon Schnittker sold 476 shares of the company's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.75% of the company's stock.

Hedge Funds Weigh In On Hologic

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new position in Hologic in the second quarter valued at approximately $25,000. Wolff Wiese Magana LLC acquired a new position in Hologic in the third quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new position in Hologic in the first quarter valued at approximately $37,000. Sunbelt Securities Inc. acquired a new position in Hologic in the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC boosted its holdings in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 416 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.